Verification that patient meets eligibility criteria. 3. Medical history and comp lete physical examination. a. Clinical evaluation, including vital signs and weight, symptom assessment and ECOG scoring. 4. CBC (complete blood count with differential and platelet count), serum chemistries (electrolytes, AST, ALT, alkaline phosphatase, bilirubin, creatinine and blood urea nitrogen (BUN)). 5. Obtain up to 110 mls peripheral blood for baseline research studies. 6. Patients of child bearing potential must have a negative urine pregnancy test. 7. Vaccination will be administered i.d. (intradermal) at the s ite of previous primary vaccine series. 8. Post immunization monitoring: The patients will be observed for at least 60 minutes post immunization. Vital signs will be done at least 60 minutes post vaccination. B. 48 hours after Booster Vaccination #1 1. Delaye d type hypersensitivity (DTH) will be evaluated at the injection site approximately 48 hours (+24 hours) after the booster vaccine and the DTH response (i.e. induration and erythema) measured in mm 2.